利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

391 条记录 (耗时 0.02 秒)

    IDO/TDO Inhibitor
    4.
    发明申请
    IDO/TDO Inhibitor 审中-公开

    公开(公告)号：US20200239452A1

    公开(公告)日：2020-07-30

    申请号：US16755953

    申请日：2018-10-17

    申请人： GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION ,  CanBas Co., Ltd.

    发明人： Akira Asai ,  Naohisa Ogo ,  Daisuke Muraoka ,  Osamu Takikawa ,  Takumi Kawabe ,  Takuji Sato

    IPC分类号： C07D403/12 ,  C07C335/32 ,  C07D209/42 ,  C07D409/14 ,  C07D213/81 ,  C07C391/00 ,  C07D241/42 ,  C07D333/54 ,  C07D333/18 ,  C07D213/32 ,  A61P35/04

    摘要： A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R1 and R2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R1 and R2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R4 represents, for example, —C(═NH)—HN2, and R6 represents, for example, a substituted or unsubstituted aryl group].